The TARDIS assay could be used in studies to identify appropriate candidates for discontinuation of immune checkpoint inhibitors.
Investigators in Austria studied overall survival in 914 patients diagnosed with mRCC from July 1985 to September 2020.
Study provides preliminary data on triple therapy for advanced RCC while clinicians await definitive answers from the ongoing phase 3 COSMIC-313 trial.
Investigators examined outcomes of robotic radiosurgery in patients with lung, visceral, and lymph node metastases from renal cell carcinoma.
Strategies, such as booster doses, appear warranted in this population.
Use of immune checkpoint inhibitors for any line of treatment was beneficial, investigators reported.
Patients with poor performance status have been excluded from pivotal trials on metastatic renal cell carcinoma.
Investigators describe the type and frequency of adverse reactions and how clinicians managed them.